Marengo Therapeutics
1 known investors
Marengo Therapeutics develops TCR-targeting antibodies to activate T cell subsets against cancer. The clinical-stage biotech company uses novel immunotherapy approaches to enable the body's immune system to mount durable responses to cancer and other diseases.